Titration schedule of Rybelsus is as follows: Formulation R1 (3 mg, 7 mg, 14 mg) Weeks 14 (Days 130): 3 mg once daily (This is the starting dose that may not be effective for glycemic control) Weeks 58 (Days 3160): 7 mg once daily Weeks 9 and onwards (Day 61+): Maintain 7 mg once daily if adequate control is achieved Increase to 14 mg once daily if additional glycemic control needed Formulation R2 (1.5 mg, 4 mg, 9 mg) Week 14 (Days 130): 1.5 mg once daily Week 58 (Days 3160): 4 mg once daily Week 9 onward (Day 61+): Maintain 4 mg once daily if adequate control is achieved or, Increase to 9 mg once daily if additional glycemic control is needed Why a conversion chart matters Liraglutide, semaglutide, and dulaglutide are GLP-1 agonists, but they have different active ingredients, indications, efficacy, and potencies
Published Phase 2 data (NEJM, 2023) showed retatrutide achieving up to 24.2% mean weight reduction at 48 weeks exceeding outcomes seen with dual GLP-1/GIP agonists
The results showed that the participants in the semaglutide group lost 15.8% of their body weight compared to 6.4% in the liraglutide group
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
